Bright Minds Biosciences Inc. develops therapeutics aimed at improving the lives of patients with severe diseases. While the company has a strong liquidity position with a current ratio of 86.56 and no debt, it faces concerns with negative returns on equity and assets, indicating operational inefficiencies. The recent price drop of 5.64% may reflect market skepticism, despite its promising biotechnology focus. Overall, the financial health score of 75 suggests potential, but the negative ROE and ROA warrant caution for investors.
Loading financial metrics...
Company posted a loss of $-8.9M over the last year, representing Infinity% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $7.9M over the last year.
Fortress balance sheet: cash covers total debt 364×, providing significant financial flexibility.
Excellent liquidity with current ratio of 86.6x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q2 (June 30, 2025)